The disclosure is based, at least in part, on certain human monoclonal antibodies , or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS – CoV – 2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS – CoV – 2 infections and are suitable for use in therapeutic methods to protect individuals from SARS – CoV – 2 infections.
Date of Application
June 9, 2022
James Kobie, Michael Piepenbrink, Paul Gopefert, Mark R. Walter, Nathan Erdmann, Ashlesha Deshpande, Luis Martinez-Sobrido and Jun-Gyu Park